

IN THE CLAIMS:

Please amend claims 35-38 as follows:

35. (Amended) The method according to claim 34 wherein the inhibitors of TGF β are selected from proteins, glycoproteins and proteoglycans.

36. (Amended) The method according to claim 35 wherein the protein inhibitors of TGF β are selected from antibodies and peptide growth factors.

37. (Amended) The method according to claim 35 wherein the glycoprotein inhibitors of TGF β are selected from α_2 -macroglobulin, laminin and collagen.

*Sub
KJZ*
38. (Amended) The method according to claim 35 wherein the proteoglycan inhibitors of TGF β are selected from decorin, heparin sulfate proteoglycans and biglycan.

REMARKS

35 U.S.C. § 101/112 Rejections

In the June 7, 2001 Office action, claims 35-38 were rejected under 35 U.S.C. § 101 as being the claimed recitation of a use, without setting forth any steps involved in the process, thereby resulting in an improper definition of a process. Further, claims 35-38 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite because the expression "The use" fails to clarify either a composition or method of use intended. In response to the Section 101